Press Releases

GlobeNewswire, Inc.

LAS VEGAS, NEVADA, Oct. 07, 2026 (GLOBE NEWSWIRE) -- Avaí Bio, Inc. (OTCQB: AVAI) (“Avaí” or the “Company”) and its joint venture partner Austrianova, today announced the first joint steering committee meeting for their collaboration with Ospedale...

GlobeNewswire, Inc.

MILAN, Oct. 04, 2026 (GLOBE NEWSWIRE) -- AAVantgarde Bio (AAVantgarde), the clinical-stage biotechnology company developing genetic medicines for inherited retinal diseases (IRDs) using its proprietary dual-AAV technology, has today announced the...

MENAFN

(MENAFN) An estimated 995 people died of heat-related causes in Austria from June to August 2026, the most since tracking began in 2017, the Austrian Agency for Health and Food Safety (AGES) said Friday.

EIN Presswire

Mitch-Stuart expands its 2027 travel catalog with new global destinations for nonprofit auctions and corporate incentives.

GlobeNewswire, Inc.

SAN DIEGO, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio®” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have...

GlobeNewswire, Inc.

LAS VEGAS, NEVADA, Sept. 30, 2026 (GLOBE NEWSWIRE) -- Avaí Bio, Inc. (OTCQB: AVAI) (“Avaí” or the “Company”), an emerging biotech developing transformative cell-based therapies for diabetes, age-related disorders, and anti-aging, together with its...

GlobeNewswire, Inc.

PHACT™ CB0104A earned BPI Commercial and Home Compostable, TÜV AUSTRIA OK compost HOME & OK compost INDUSTRIAL Certifications New all-PHA compound is designed for cutlery, caps, enclosures, beauty packaging, and agriculture, and horticulture...

GlobeNewswire, Inc.

In the Phase 3 open-label extension clinical trial (OLE), patients with moderate to severe acne received denifanstat for up to 52 weeks, including prior placebo patients Denifanstat showed progressive and sustained improvements across all efficacy...

GlobeNewswire, Inc.

Vail, CO, Sept. 30, 2026 (GLOBE NEWSWIRE) -- U.S. Ski & Snowboard has announced the promotion of Thomas R. Hackett, M.D., to Chief Medical Officer (CMO). Dr. Hackett, a complex knee and shoulder surgeon at The Steadman Clinic and sports medicine...

GlobeNewswire, Inc.

Phase 2a MAINSAIL Trial of NAV-240 in Hidradenitis Suppurativa (HS) Recruiting Ahead of Schedule Early Cohorts in Phase 1 Study of Next-Generation Subcutaneous Bispecific Antibody NAV-242 Indicate Extended Half Life (HLE) on Path to Goal of...

GlobeNewswire, Inc.

EGL-003, a selective IL-2 agonist, was well tolerated across all four dose cohorts.

GlobeNewswire, Inc.

Ad hoc announcement pursuant to Art. 53 LR. A conference call will be held on September 30, 2026, at 14:00 CEST / 13:00 BST / 08:00 EDT. Details are at the end of this news release Strong momentum and expanding global access position AGAMREE® for...

GlobeNewswire, Inc.

The Phase I clinical trial will evaluate a proprietary drug candidate formulated using Cyprumed’s oral tablet technology, marking the first Cyprumed technology program to enter human clinical development The milestone triggers a payment to...

GlobeNewswire, Inc.

SAN DIEGO, Sept. 28, 2026 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio®” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have...

GlobeNewswire, Inc.

SAN CARLOS, Calif., Sept. 28, 2026 (GLOBE NEWSWIRE) -- Attovia Therapeutics, Inc. (“Attovia”) (Nasdaq: ATTO), a clinical-stage biopharmaceutical company developing next-generation biotherapeutics for immune-mediated diseases with high unmet need,...

GlobeNewswire, Inc.

Data will be presented in two top-rated oral presentations Meet the Expert session offers insights into Actinium-225 production Garching / Munich, October 7, 2026 — ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech...

GlobeNewswire, Inc.

LAS VEGAS, NEVADA, Sept. 24, 2026 (GLOBE NEWSWIRE) -- Avaí Bio, Inc. (OTCQB: AVAI) (“Avaí” or the “Company”), together with joint venture partner Austrianova, today announced that Prof. Walter H. Günzburg presented the companies’ encapsulated-cell...

GlobeNewswire, Inc.

Dr. Nora Dimon, VP of Clinical Development, to present preclinical findings on the Company’s lead retinal program, CoTx-101, including non-human primate data Rodolphe Clerval, CEO, to deliver a corporate presentation at the Euretina Innovation...

GlobeNewswire, Inc.

CAMBRIDGE, Mass., Oct. 06, 2026 (GLOBE NEWSWIRE) -- OHB Pediatrics Ltd d/b/a Oak Hill Bio, a clinical-stage rare disease therapeutics company, today announced the appointment of Joerg Hipp, PhD as Chief Translational Science Officer.

Office of the Governor Delaware

FOR IMMEDIATE RELEASE Thursday, September 17, 2026 Media Contact: Jonah Anderson jonah.anderson@delaware.gov SMYRNA, Del. — Joined by state leaders, residents, staff, and members of the Cain family, Governor Matt Meyer today signed legislation...